Modality
Cell Therapy
MOA
RAS(ON)i
Target
CFTR
Pathway
Notch
Parkinson'sFTD
Development Pipeline
Preclinical
May 2018
→ Mar 2030
PreclinicalCurrent
NCT04989521
2,385 pts·FTD
2018-05→2029-01·Active
NCT07774206
1,197 pts·Parkinson's
2019-04→2030-03·Terminated
3,582 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-01-102.8y awayInterim· FTD
2030-03-073.9y awayInterim· Parkinson's
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Active
Preclinical
Termina…
Catalysts
Interim
2029-01-10 · 2.8y away
FTD
Interim
2030-03-07 · 3.9y away
Parkinson's
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04989521 | Preclinical | FTD | Active | 2385 | UPCR |
| NCT07774206 | Preclinical | Parkinson's | Terminated | 1197 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| 180-3597 | Innovent Bio | Preclinical | SHP2 |